154 related articles for article (PubMed ID: 33000341)
1. Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study.
Herden J; Schwarte A; Werner T; Behrendt U; Heidenreich A; Weissbach L
World J Urol; 2021 Jul; 39(7):2515-2523. PubMed ID: 33000341
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
Herden J; Schwarte A; Boedefeld EA; Weissbach L
Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
[TBL] [Abstract][Full Text] [Related]
3. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
6. [Patterns of care of patients with localized prostate cancer in Germany: a health care study with focus on active surveillance].
Chun FK; Becker A; Kluth LA; Seiler D; Schnell D; Fisch M; Graefen M; Weissbach L
Urologe A; 2015 Jan; 54(1):6-13. PubMed ID: 25391440
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?
Herden J; Heidenreich A; Weissbach L
BJU Int; 2017 Aug; 120(2):212-218. PubMed ID: 27862832
[TBL] [Abstract][Full Text] [Related]
8. A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center.
Becker A; Seiler D; Kwiatkowski M; Kluth LA; Schnell D; Graefen M; Schlomm T; Fisch M; Recker F; Weissbach L; Chun FK
World J Urol; 2014 Aug; 32(4):891-7. PubMed ID: 24820259
[TBL] [Abstract][Full Text] [Related]
9. [Noninvasive treatment of organ-confined prostate cancer in elderly patients-results of the HAROW study].
Herden J; Boedefeld EA; Weißbach L
Urologe A; 2020 Apr; 59(4):450-460. PubMed ID: 32025749
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study.
Herden J; Wille S; Weissbach L
BJU Int; 2016 Aug; 118(2):258-63. PubMed ID: 26332209
[TBL] [Abstract][Full Text] [Related]
11. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
13. HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer.
Weissbach L; Stuerzebecher S; Mumperow E; Klotz T; Schnell D
World J Urol; 2016 May; 34(5):641-7. PubMed ID: 26373955
[TBL] [Abstract][Full Text] [Related]
14. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
16. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
[TBL] [Abstract][Full Text] [Related]
17. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
18. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F;
Eur Urol; 2011 Jan; 59(1):61-71. PubMed ID: 21056534
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]